Pharma

Your Article Summary

See Latest Articles

FDA Advisory Committee Hears Presentations and Public Comment on EXALGO Extended-Release Tablets
Covidien, 09/28/09

Covidien, a leading global provider of healthcare products, announced that it presented information to members of a U.S. Food and Drug Administration Advisory Committee on the New Drug Application and proposed Risk Evaluation and Mitigation Strategy program for EXALGOTM tablets, an opioid formulation. At a meeting held in Gaithersburg, Md., committee members also heard public comments about the analgesic. Covidien will now await FDA's decision on EXALGO approval.

Today in Drug/Product Approvals...keeping you current

Receive free subspecialty "5-minute updates" via email

Ustekinumab (Stelara): First-in-class human monoclonal antibody approved for treatment of moderate-to-severe plaque psoriasis
Formulary , 12/02/09

Safety concerns slow new drug review and approval processes
Formulary , 12/02/09

Teva Announces The Submission Of A Biologics License Application (BLA) For XM02 For The Treatment Of Chemotherapy-Induced Neutropenia
Teva Pharmaceutical Industries, 12/02/09

 See all of Drug/Product Approvals